美國批准了首個治療花生過敏的藥

The US has approved its first treatment for peanut allergies in children.
美國首次批准治療兒童花生過敏。
The drug AR101, or Palforzia, uses oral immunotherapy, with children given tiny but increasing amounts of peanut protein over a six-month period under medical supervision.
這個藥物叫作AR101，或Palforzia，採用口服免疫療法，六個月的醫學觀察期內可以給兒童少量花生蛋白，並逐漸加量。
After that, users must continue to take a daily dose to be able to tolerate accidental exposure.
然後，服藥者必須每天堅持吃點，以便在意外接觸花生時能挺住。
The treatment is not a cure and makers warn that the risk of a potentially fatal anaphylactic reaction remains.
這一療法不能根治，製藥商警告說依然存在潛在致命過敏反應。
And patients must continue to avoid peanuts in their diet.
病人飲食依舊不能含有花生。
Peanuts are the most common food allergen in the US, with an increase in the number of those affected by food allergies across the West in recent decades.
花生是美國最常見的食物過敏原，近些年在西方受食物過敏影響人數有所上升。
While trials to desensitise patients with peanut allergies have previously taken place in the US and elsewhere, the drug is the first to be approved by the US Food and Drug Administration (FDA). The drug has not yet been authorised for use in the UK.
雖然此前美國和其他地區進行過花生過敏患者的脫敏試驗，但這是首個經美國食品藥品監督管理局批准的藥品，但在英國尚未獲準使用。
Palforzia, which has been approved for use in patients aged between four and 17, comes in the form of a powder which is sprinkled on food.
Palforzia藥物獲准用於4至17歲患者的治療，以粉末形式灑在食物上。
Last year, scientists at King's College London said that oral immunotherapy offered "protection but not a cure" for peanut allergies, with treatment only effective while patients continued taking small amounts of the allergen.
去年倫敦國王學院的科學家說口服免疫療法對於花生過敏者只能“起到保護作用，卻不能根治”，而且患者要一直吃少量過敏原食物這種療法纔有效。